.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Immunotherapy has revolutionized the management of liver cancer. Recent research highlights significant breakthroughs in advanced HCC immunotherapy survival, suggesting that a subset of patients may even achieve a functional cure. By using mixture cure models, researchers can now estimate the proportion of long-term survivors who reach a stable plateau in their survival curves.
Data from pivotal phase 3 trials provide a clearer picture of these outcomes. In the HIMALAYA trial, the combination of durvalumab and tremelimumab resulted in a 12.8% long-term survival rate after five years. This significantly outperformed sorafenib, which showed only 5.2%. Similarly, the RATIONALE-301 trial demonstrated that tislelizumab monotherapy achieved a 25.2% long-term survival rate.
The CheckMate9DW study also offered promising insights into the cure fraction. This trial compared nivolumab-ipilimumab against standard tyrosine kinase inhibitors. The results indicated a cure fraction of 17.8% for the immunotherapy group, while the control group reached only 3.5%. These findings suggest that dual checkpoint inhibition significantly enhances the likelihood of durable remission.
Clinical practice data often differ from controlled trials. However, a large cohort of 1,581 patients treated with atezolizumab-bevacizumab mirrored these trial results. In this real-world setting, long-term survival was 12.3%, and the cure fraction stood at 7.9%.
Identifying which patients will benefit most is crucial. Analysis shows that the ALBI score and the presence of hepatitis C are strong predictors of long-term survival. Additionally, albumin levels and hepatitis C status help clinicians estimate the potential cure fraction. Consequently, these biomarkers allow for more personalized treatment planning in oncology.
A cure fraction refers to the estimated proportion of patients who experience long-term, stable survival without disease progression, effectively reaching a plateau where their mortality risk aligns with the general population.
Combinations like durvalumab-tremelimumab and nivolumab-ipilimumab have demonstrated superior long-term survival and higher cure fractions compared to traditional sorafenib or lenvatinib treatments.
Real-world data for atezolizumab-bevacizumab show a long-term survival rate of approximately 12.3%, which is highly consistent with the 10-15% range observed across various major clinical trials.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Evidence from clinical trials and real-world data shows that immunotherapy combinations achieve 10-15% long-term survival and 7-9% cure fractions in advance...
6 months ago
A multicenter study from Southeastern Türkiye identified rare alpha-1 antitrypsin deficiency variants, including the homozygous Malton genotype, among COPD patients. Half were never-smokers, highlighting the critical need for comprehensive genetic screening beyond common S and Z alleles.
Today
A comprehensive scoping review synthesises evidence linking prenatal maternal mental health to long-term offspring neurodevelopment, evaluating neuroendocrine, inflammatory, and epigenetic pathways while highlighting clinical screening and future research priorities.
Today
The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today
A 25-year multi-institutional cohort reveals high recurrence rates in pediatric giant cell tumor of bone, particularly in patients with open physes and bone marrow edema on preoperative MRI. Early surveillance and careful balance between growth plate preservation and tumor clearance are essential.
Today
India is advancing preventive healthcare by integrating genomics, artificial intelligence, and quantum technologies. With the SANGAM programme sequencing one million Indian genomes, clinicians can unlock personalized therapies, detect cardiometabolic risks early, and curb the burden of diabetes and heart disease.
Today
